Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Iovance Biotherapeutics (IOVA) Gross Profit (2023 - 2025)

Iovance Biotherapeutics has reported Gross Profit over the past 3 years, most recently at $43.7 million for Q4 2025.

  • Quarterly results put Gross Profit at $43.7 million for Q4 2025, up 21.6% from a year ago — trailing twelve months through Dec 2025 was $75.5 million (up 34.52% YoY), and the annual figure for FY2025 was $90.3 million, up 27.53%.
  • Gross Profit for Q4 2025 was $43.7 million at Iovance Biotherapeutics, up from $29.0 million in the prior quarter.
  • Over the last five years, Gross Profit for IOVA hit a ceiling of $43.7 million in Q4 2025 and a floor of -$6.5 million in Q1 2024.
  • Median Gross Profit over the past 3 years was $3.3 million (2025), compared with a mean of $12.0 million.
  • Peak annual rise in Gross Profit hit 1354.96% in 2025, while the deepest fall reached 7.18% in 2025.
  • Iovance Biotherapeutics' Gross Profit stood at $5.8 million in 2023, then surged by 514.92% to $35.9 million in 2024, then rose by 21.6% to $43.7 million in 2025.
  • The last three reported values for Gross Profit were $43.7 million (Q4 2025), $29.0 million (Q3 2025), and $3.3 million (Q2 2025) per Business Quant data.